Literature DB >> 26883701

Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulcerans.

Nicole Scherr1, Gerd Pluschke2, Manoranjan Panda3.   

Abstract

A library of compounds covering a broad chemical space was selected from a tuberculosis drug development program and was screened in a whole-cell assay against Mycobacterium ulcerans, the causative agent of the necrotizing skin disease Buruli ulcer. While a number of potent antitubercular agents were only weakly active or inactive against M. ulcerans, five compounds showed high activity (90% inhibitory concentration [IC90], ≤1 μM), making screening of focused antitubercular libraries a good starting point for lead generation against M. ulcerans.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26883701      PMCID： PMC4862464          DOI： 10.1128/AAC.02658-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Authors:  Baohong Ji; Sébastien Lefrançois; Jerome Robert; Aurélie Chauffour; Chantal Truffot; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis.

Authors:  Shahul Hameed P; Suresh Solapure; Kakoli Mukherjee; Vrinda Nandi; David Waterson; Radha Shandil; Meenakshi Balganesh; Vasan K Sambandamurthy; Anand Kumar Raichurkar; Abhijeet Deshpande; Anirban Ghosh; Disha Awasthy; Gajanan Shanbhag; Gulebahar Sheikh; Helen McMiken; Jayashree Puttur; Jitendar Reddy; Jim Werngren; Jon Read; Mahesh Kumar; Manjunatha R; Murugan Chinnapattu; Prashanti Madhavapeddi; Praveena Manjrekar; Reetobrata Basu; Sheshagiri Gaonkar; Sreevalli Sharma; Sven Hoffner; Vaishali Humnabadkar; Venkita Subbulakshmi; Vijender Panduga
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.

Authors:  K M George; D Chatterjee; G Gunawardana; D Welty; J Hayman; R Lee; P L Small
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

Review 4.  Toxic effects and drug interactions of antimycobacterial therapy.

Authors:  N H Chan-Tompkins
Journal:  Clin Dermatol       Date:  1995 May-Jun       Impact factor: 3.541

5.  In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.

Authors:  A M Dhople
Journal:  Int J Antimicrob Agents       Date:  2001-01       Impact factor: 5.283

6.  Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents.

Authors:  Pravin S Shirude; Beena Paul; Nilanjana Roy Choudhury; Chaitanya Kedari; Balachandra Bandodkar; Bheemarao G Ugarkar
Journal:  ACS Med Chem Lett       Date:  2012-08-13       Impact factor: 4.345

7.  Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.

Authors:  A Bentoucha; J Robert; H Dega; N Lounis; V Jarlier; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.

Authors:  V Balasubramanian; S Solapure; H Iyer; A Ghosh; S Sharma; P Kaur; R Deepthi; V Subbulakshmi; V Ramya; V Ramachandran; M Balganesh; L Wright; D Melnick; S L Butler; V K Sambandamurthy
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

9.  Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.

Authors:  Nicole Scherr; Gerd Pluschke; Charles J Thompson; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2015-08-13

10.  Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens.

Authors:  Martin W Bratschi; Miriam Bolz; Leticia Grize; Sarah Kerber; Jacques C Minyem; Alphonse Um Boock; Dorothy Yeboah-Manu; Marie-Thérèse Ruf; Gerd Pluschke
Journal:  BMC Infect Dis       Date:  2014-11-30       Impact factor: 3.090
View more
  5 in total

1.  Determination of Bioenergetic Parameters in Mycobacterium ulcerans.

Authors:  Sangeeta Susan Thomas; Kevin Pethe
Journal:  Methods Mol Biol       Date:  2022

2.  Overview: Development of Drugs Against Mycobacterium ulcerans.

Authors:  Gerd Pluschke; Katharina Röltgen
Journal:  Methods Mol Biol       Date:  2022

3.  In Silico Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa.

Authors:  Samuel K Kwofie; Bismark Dankwa; Emmanuel A Odame; Francis E Agamah; Lady P A Doe; Joshua Teye; Odame Agyapong; Whelton A Miller; Lydia Mosi; Michael D Wilson
Journal:  Molecules       Date:  2018-06-27       Impact factor: 4.411

4.  Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification.

Authors:  Sherine E Thomas; Andrew J Whitehouse; Karen Brown; Sophie Burbaud; Juan M Belardinelli; Jasper Sangen; Ramanuj Lahiri; Mark Daben J Libardo; Pooja Gupta; Sony Malhotra; Helena I M Boshoff; Mary Jackson; Chris Abell; Anthony G Coyne; Tom L Blundell; Rodrigo Andres Floto; Vítor Mendes
Journal:  Nucleic Acids Res       Date:  2020-08-20       Impact factor: 16.971

5.  Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.

Authors:  María Pilar Arenaz-Callao; Rubén González Del Río; Ainhoa Lucía Quintana; Charles J Thompson; Alfonso Mendoza-Losana; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.